Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
Jordi Rodón(The University of Texas MD Anderson Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), Jean‐Charles Soria(Inserm), Gerald Batist(Jewish General Hospital), Richard L. Schilsky(American Society of Clinical Oncology), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Wilson H. Miller(Jewish General Hospital), Alexander M.M. Eggermont(University Medical Center Utrecht), Catherine Bresson(WIN Consortium), Raanan Berger(Tel Aviv University), Amir Onn(Tel Aviv University), Vladimir Lazar(Institut Gustave Roussy), John Mendelsohn(Unknown), Eitan Rubin(Ben-Gurion University of the Negev)
Cited by 75
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k